Society for Translational Oncology


Highlights from STO's educational activities, including content associated with the Society and its journal The Oncologist. RSS Feed URL

Society for Translational Oncology navigateright Episode

RET As a Target in Lung Cancer

Rearranged during transfection (RET) proto-oncogene rearrangements have been validated as an additional oncogenic driver that occurs in 1-2% of NSCLC. Prior efforts to target RET in lung cancer patients were hampered by the lack of potent and selective RET tyrosine kinase inhibitors (TKIs), necessitating the re-purposed use of multikinase inhibitors such as cabozantinib or vandetanib, which are encumbered by suboptimal efficacy and significant toxicities. Recently, novel, oral, highly potent, and selective RET TKIs—BLU-667 (pralsetinib) and LOXO-292 (selpercatinib)—have entered the clinic.

Video Overview:

Jessica J. Lin, MD

Massachusetts General Hospital

STO gratefully acknowledges educational grants in partial support of this activity from:
Agios Pharmaceuticals
Celgene Corporation
Novartis Pharmaceuticals Corp.
Pfizer Inc.